Is Trillium Therapeutics a good dividend stock?

Trillium Therapeutics (TSE:TR) pays an annual dividend of C$0.36 per share and currently has a dividend yield of 0.00%.

What other stocks do shareholders of Trillium Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Cedar Fair (FUN) , Trillium Therapeutics (TRIL) , Ford Motor (F) , Express Scripts (ESRX) , Esperion Therapeutics (ESPR) , ConocoPhillips (COP) , Canadian Natural Resources (CNQ) , bluebird bio (BLUE) and Biogen (BIIB) .

How do I buy shares of Trillium Therapeutics?

Shares of TR stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor , Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. Compare Top Brokerages Here .

TSE:TR

Trillium Therapeutics (TR) Stock Price, News & Analysis

→ Uncover this 2024 Hidden Gem (From Tips4Traders) (Ad)

Free TR Stock Alerts

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 49,075 shs
Average Volume: 99,071 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Trillium Therapeutics alerts:

Ad Insiders Exposed

This consistently signaled gains of 453%... 610%... and even 1036%...

It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.

About Trillium Therapeutics Stock (TSE:TR)

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (''do not eat'') signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (''eat'') signals. A Phase one clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with cancer is ongoing, and a second Phase one trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17.

Ad Insiders Exposed

This consistently signaled gains of 453%... 610%... and even 1036%...

TR Stock News Headlines

April 15, 2024 | finance.yahoo.com

Sezary Syndrome Pipeline Insights 2024, Featuring Major Players 4SC, Seagen, Merck Sharp & Dohme, Innate Pharma, Trillium Therapeutics and Secura Bio

April 2, 2024 | finance.yahoo.com

Upstream Bio Announces Appointment of Rand Sutherland as CEO and Additions to Leadership Team

April 18, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

March 12, 2024 | finance.yahoo.com

Ratio Announces Expansion of Manufacturing Agreement with PharmaLogic for FAP-Targeted Radiopharmaceuticals

January 17, 2024 | bizjournals.com

Ratio Therapeutics raises $50M for tumor-targeting radiopharmaceuticals

June 22, 2023 | finance.yahoo.com

Tvardi Therapeutics Announces First Patients Dosed in its Phase 2 Liver Cancer Trial Using TTI-101, a Novel STAT3 Inhibitor

June 20, 2023 | benzinga.com

PD-1 Non-Small Cell Lung Cancer Clinical Trials Pipeline Analysis: 20+ Companies are Working to Improve the Treatment Space | DelveInsight

May 9, 2023 | finance.yahoo.com

Ratio Therapeutics Announces Opening of New Research and Development Facility

April 18, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

April 25, 2023 | finance.yahoo.com

Trillium Engineering Announces Its Latest Innovation in Cameras Utilizing AI Technology - HD80-AIM

March 10, 2023 | msn.com

Who's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In Person

February 6, 2023 | finanznachrichten.de

Viridian Therapeutics, Inc: Viridian Appoints Scott Myers as President and Chief Executive Officer

January 28, 2023 | detroitnews.com

Taylor Trillium building into Division 4 state power, behind coach Terrell George

December 19, 2022 | benzinga.com

Leiomyosarcoma Drug Pipeline Research Report 2022: Comprehensive Insights on 18+ Companies and 18+ Pipeline Drugs

December 6, 2022 | finance.yahoo.com

Ratio Therapeutics Appoints Reed Malleck as Chief Financial Officer

November 3, 2022 | seekingalpha.com

Pfizer: Q3 Earnings Review - Planning For Life After COVID

August 8, 2022 | msn.com

Cash-rich Pfizer snaps up Global Blood Therapeutics for $5.4 billion

May 22, 2022 | seekingalpha.com

Pfizer: Management's M&A Activity Is Winning Me Over

May 18, 2022 | finanznachrichten.de

Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Positive Results from Phase 1 Dose-Escalation Study of its Lead Compound TTI-0102

May 18, 2022 | stockhouse.com

Thiogenesis Announces Positive Results from Phase 1 Dose-Escalation Study of its Lead Compound TTI-0102

May 14, 2022 | msn.com

3 Dirt-Cheap Stocks You Can Buy Right Now

May 10, 2022 | baystreet.ca

Pfizer Buys Biohaven for $11.6B

February 17, 2022 | morningstar.com

NeonMind to Open its Inaugural Specialty Mental Health Clinic in Mississauga, Ontario

January 25, 2022 | yahoo.com

$51,300 OTF Grant helped breast cancer patients in Ontario access educational resources during the pandemic

January 12, 2022 | finance.yahoo.com

TCR² Therapeutics Announces Experienced Biotech Executive Rosemary Harrison as Chief Business and Strategy Officer

December 20, 2021 | apnews.com

Sensorion appoints pharmaceutical industry veteran Scott D. Myers as Chairman of the Board and Independent Director

November 17, 2021 | law360.com

Pfizer's $2.3B Trillium Deal Closes Without FTC Challenge

See More Headlines

Receive TR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: TSE
Sector: N/A
Industry: N/A
Sub-Industry: N/A
Current Symbol: TSE:TR
CUSIP: N/A
CIK: N/A
Web: www.trilliumtherapeutics.com
Phone: +1-416-5950627
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Calvin R. Stiller M.D.
Independent Chairman of the Board
Niclas Stiernholm
President, Chief Executive Officer, Director
James T. Parsons
Chief Financial Officer
Malik Slassi
Senior Vice President - Discovery Research
Robert Uger
Chief Scientific Officer
Scott Duncan
Director of Intellectual Property
Penka Petrova
Chief Development Officer
Eric L Sievers
Chief Medical Officer
Luke M. Beshar CPA (Age 59)
Independent Director
Henry Friesen M.D. (Age 79)
Independent Director

TR Stock Analysis - Frequently Asked Questions

Is Trillium Therapeutics a good dividend stock?: Trillium Therapeutics (TSE:TR) pays an annual dividend of C$0.36 per share and currently has a dividend yield of 0.00%.
What other stocks do shareholders of Trillium Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Cedar Fair (FUN), Trillium Therapeutics (TRIL), Ford Motor (F), Express Scripts (ESRX), Esperion Therapeutics (ESPR), ConocoPhillips (COP), Canadian Natural Resources (CNQ), bluebird bio (BLUE) and Biogen (BIIB).
How do I buy shares of Trillium Therapeutics?: Shares of TR stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:TR) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Trillium Therapeutics (TR) Stock Price, News & Analysis

About Trillium Therapeutics Stock (TSE:TR)

TR Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

TR Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info